Publication | Open Access

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Phase 1/2Hematological MalignancyPivekimab SunirineMedicineImmunologyImmunotherapyOncologyCell BiologyMyeloid Neoplasia